Consequently, understanding how small molecules like EGCG can modulate the behavior of these domains offers valuable insights into potential therapeutic approaches for ALS and other TDP-43-related pathological conditions. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.